Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DRMA Dermata Therapeutics Inc

Pre-Mkt 05-11 07:20:01 EDT

1.26

-0.04

-3.08%

盘前1.30

+0.04+3.17%

07:09 EDT

High1.32	Low1.25	Vol38.69K
Open1.25	D1 Closing1.30	Amplitude5.38%
Mkt Cap5.07M	Tradable Cap3.51M	Total Shares4.02M
T/O49.51K	T/O Rate1.39%	Tradable Shares2.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DRMA","market":"US","secType":"STK","nameCN":"Dermata Therapeutics Inc","latestPrice":1.26,"timestamp":1778270400000,"preClose":1.3,"halted":0,"volume":38691,"hourTrading":{"tag":"盘前","latestPrice":1.3,"preClose":1.26,"latestTime":"07:09 EDT","volume":427,"amount":550.3700355999999,"timestamp":1778497768112,"change":0.04,"changeRate":0.031746,"amplitude":0.02381},"delay":0,"changeRate":-0.030769230769230795,"floatShares":2784800,"shares":4022100,"eps":-8.160896,"marketStatus":"Pre-Mkt","change":-0.04,"latestTime":"05-11 07:20:01 EDT","open":1.25,"high":1.32,"low":1.25,"amount":49511.2554162,"amplitude":0.053846,"askPrice":1.39,"askSize":2000,"bidPrice":1.29,"bidSize":85,"shortable":3,"etf":0,"ttmEps":-8.160896,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778506200000},"marketStatusCode":1,"adr":0,"listingDate":1628827200000,"exchange":"NASDAQ","adjPreClose":1.26,"preHourTrading":{"tag":"盘前","latestPrice":1.3,"preClose":1.26,"latestTime":"07:09 EDT","volume":427,"amount":550.3700355999999,"timestamp":1778497768112,"change":0.04,"changeRate":0.031746,"amplitude":0.02381},"postHourTrading":{"tag":"盘后","latestPrice":1.29,"preClose":1.26,"latestTime":"17:17 EDT","volume":470,"amount":595.47,"timestamp":1778275035392,"change":0.03,"changeRate":0.02381,"amplitude":0.02381},"volumeRatio":0.7219328146321158},"requestUrl":"/m/hq/s/DRMA","defaultTab":"news","newsList":[{"id":"2634460631","title":"Dermata Therapeutics Inc  expected to post a loss of 53 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634460631","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634460631?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:53","pubTimestamp":1778277185,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc  expected to post a loss of53cents a share - Earnings Preview Dermata Therapeutics Inc DRMA.OQ DRMA.O is expected to  report resultson May 12 (estimated) for the period ending","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2QE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625886931","title":"Dermata Therapeutics announces annual shareholder meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2625886931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625886931?lang=en_us&edition=fundamental","pubTime":"2026-04-07 18:01","pubTimestamp":1775556115,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics annual shareholder meeting set for May 27, 2026 in virtual format.Shareholders to vote on election of three Class II directors for terms running to 2029.Ballot includes ratification of CBIZ CPAs as independent auditor for fiscal 2026.Company seeking approval to issue common shares underlying warrants from December 2025 financing, potentially exceeding 20% of shares outstanding at issuance.Items also include repricing warrants covering 120,734 shares, increase in 2021 equity plan share reserve to 402,214 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval syst","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL6xXtJv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","DRMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624509163","title":"Dermata says Australian patent application for topical dermal fillers accepted for Bioneedle system","url":"https://stock-news.laohu8.com/highlight/detail?id=2624509163","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624509163?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:32","pubTimestamp":1775133174,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics received acceptance from Australian Patent Office for patent application covering topical delivery of dermal fillers using its Bioneedle Delivery System.Patent, titled “Compositions for the treatment of conditions by dermal fillers,” is set to issue in about three months unless a third party files an opposition.Dermata already holds allowed or issued patents in US, Australia, Japan covering Bioneedle Delivery System with botulinum toxin for hyperhidrosis treatment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLLDKB1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","DRMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624758515","title":"Dermata Therapeutics price target lowered to $4 from $10 at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2624758515","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624758515?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:35","pubTimestamp":1775046912,"startTime":"0","endTime":"0","summary":"Maxim lowered the firm’s price target on Dermata Therapeutics (DRMA) to $4 from $10 and keeps a Buy rating on the shares. The company’s Q4 results ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-price-target-lowered-to-4-from-10-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-price-target-lowered-to-4-from-10-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622891421","title":"Dermata Therapeutics Q4 EPS $(1.52) Beats $(1.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891421","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891421?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:18","pubTimestamp":1774559921,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.54) by 1.3 percent. This is a 83.48 percent increase over losses of $(9.20) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51497892/dermata-therapeutics-q4-eps-1-52-beats-1-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Dermata Therapeutics Q4 EPS $(1.52) Beats $(1.54) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622891491","title":"Dermata Therapeutics FY2025 net loss narrows 38.5% to $7.6 million; cash and cash equivalents climb 138% to $8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891491?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:17","pubTimestamp":1774559838,"startTime":"0","endTime":"0","summary":"Dermata filed a Form 8-K reporting full-year 2025 results, including a net loss of USD 7.6 million.Research and development expense fell 64.27% to USD 2.9 million, primarily due to lower clinical costs after completion of the STAR-1 acne study in Q2 2025.Selling, general and administrative expense rose 12.42% to USD 4.8 million, driven mainly by USD 0.7 million in marketing expense.Cash and cash equivalents were USD 7.5 million as of Dec. 31, 2025, and the company said its cash resources are expected to fund operations into Q1 2027.Management said Dermata is pivoting to direct-to-consumer skincare under the Tome brand, with a first product launch targeted for mid-2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL2J3K1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DRMA","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620040681","title":"Dermata Therapeutics SVP Regulatory Affairs Maria E Bedoya-Toro Munera acquires USD 1,270 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620040681","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620040681?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:44","pubTimestamp":1773783897,"startTime":"0","endTime":"0","summary":"Maria Bedoya-Toro Munera, SVP of Regulatory Affairs at Dermata Therapeutics, reported the acquisition of 1,000 common shares at USD 1.27 per share. Following the transaction, she reported direct beneficial ownership of 1,012 common shares. She also reported indirect beneficial ownership of 34 common shares held through the Munera Family Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9kNvFw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Dermata Therapeutics SVP Regulatory Affairs Maria E Bedoya-Toro Munera acquires USD 1,270 in common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","DRMA","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619143637","title":"Dermata Therapeutics Inc  expected to post a loss of $1.54 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619143637","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619143637?lang=en_us&edition=fundamental","pubTime":"2026-03-14 05:14","pubTimestamp":1773436446,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc  expected to post a loss of $1.54 a share - Earnings Preview Dermata Therapeutics Inc DRMA.OQ DRMA.O is expected to  report resultson March 17 (estimated) for the period endin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N401256:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DRMA","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618958532","title":"Dermata Therapeutics appoints Kyra Peckaitis as VP of Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618958532","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618958532?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:30","pubTimestamp":1773145814,"startTime":"0","endTime":"0","summary":"Dermata appointed Kyra Peckaitis as vice president of marketing to lead the launch of its Tome skincare brand. Peckaitis previously served as associate director of brand marketing at Coterie. She also held roles on HubSpot’s global brand team and at Sweetgreen’s integrated marketing team.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL74GBns:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BMPRXN33.USD","BK4539","BK4023","HUBS","BK4585","LU2095319765.USD","BK4007","BK4588","SG","BK4139","IE00B19Z9P08.USD","LU2210150020.SGD","IE00B894F039.SGD","IE00BZ9MQY76.HKD","IE00BMPRXR70.SGD","BK4209","LU2054465674.USD","DRMA","BK4613","LU2210149790.SGD","BK4528","IE00B19Z9Z06.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617287955","title":"Dermata Therapeutics Unveils Tome Skincare Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2617287955","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617287955?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:00","pubTimestamp":1772719214,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. announced the branding of its new consumer skincare line, Tome, positioning it as “skintech at home” and part of a strategic shift toward becoming a consumer-facing company. The company said it expects to launch its first Tome product, an over-the-counter once-weekly acne and resurfacing treatment, in mid-2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL2TvWFh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DRMA","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614405621","title":"Dermata Therapeutics Director Mary Fisher Resigns Effective March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614405621","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614405621?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:14","pubTimestamp":1772054076,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. said director Mary Fisher will resign from its board and all committee roles effective March 31, 2026. The company said her departure is not due to any disagreement and is related to her employer’s recent acquisition, which no longer allows her to serve on the board. The board will be reduced to seven members from eight.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDLfzD1C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","DRMA","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605044876","title":"Dermata Therapeutics files to sell 1.48M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2605044876","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605044876?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:05","pubTimestamp":1769119525,"startTime":"0","endTime":"0","summary":"17:03 EST Dermata Therapeutics (DRMA) files to sell 1.48M shares of common stock for holders Published first on TheFly – the ultimate source for re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-files-to-sell-1-48m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-files-to-sell-1-48m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","DRMA","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604115862","title":"Dermata Therapeutics Granted Australian Patent for Spongilla-Based Acne Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2604115862","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604115862?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:07","pubTimestamp":1768914462,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. has announced that the Australian Patent Office has granted its patent for a Spongilla technology combination as a method for treating acne. The patent, titled \"Compositions and methods for the treatment of skin conditions\" , follows a previously issued U.S. patent for the same technology. This development further strengthens Dermata's international intellectual property portfolio for its acne treatment innovations as the company prepares for the future launch of its once-weekly, over-the-counter acne treatment system. Additional patent applications are pending in other key markets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL8PSjS8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","DRMA","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595758487","title":"Dermata Therapeutics Announces $12.4 Million Private Placement With Warrants and Share Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2595758487","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595758487?lang=en_us&edition=fundamental","pubTime":"2025-12-30 05:06","pubTimestamp":1767042396,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. has announced it has entered into definitive agreements for a private placement involving the issuance and sale of approximately 2,022,062 shares of common stock , along with series C and short-term series D warrants to purchase up to 2,022,062 shares each. The securities are being offered at a purchase price of $2.04 per share or pre-funded warrant, with total gross proceeds expected to be about $4.1 million upfront and up to an additional $8.3 million if all warrants are exercised. The exercise of both series C and D warrants is contingent upon stockholder approval and will have an exercise price of $2.04 per share. Dermata intends to use the proceeds for general corporate purposes, including product launch activities, research, and potential acquisitions.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDLb9RRY8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","DRMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594218642","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2594218642","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594218642?lang=en_us&edition=fundamental","pubTime":"2025-12-27 03:31","pubTimestamp":1766777508,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics  said Wednesday it agreed to sell 2.02 million shares, along with related Series C and short-term Series D warrants, in a private placement priced at $2.04 a share, with gross proceeds of as much as $12.4 million.The stock fell 20% as intraday volume topped 617,800 shares, compared with the daily average of 537,661.Aptevo Therapeutics  will implement a 1-for-18 reverse stock split, effective at the start of trading on Tuesday.The shares fell 38% as intraday volume topped 13.6 million, compared with the daily average of 2.09 million.Price: 1.91, Change: -0.47, Percent Change: -19.62","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","APVO","BK4007","DRMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594405411","title":"Why Is Dermata Therapeutics Stock Surging Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2594405411","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594405411?lang=en_us&edition=fundamental","pubTime":"2025-12-25 00:32","pubTimestamp":1766593920,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics rose after announcing a private placement offering of common shares, Series C warrants, and Series D warrants.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/24/Ipo-Initial-Public-Offering--Business-Ma.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/24/Ipo-Initial-Public-Offering--Business-Ma.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49585324/why-is-dermata-therapeutics-stock-surging-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49585324/why-is-dermata-therapeutics-stock-surging-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","DRMA","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586602406","title":"Dermata Therapeutics: Strategic Shift and Financial Stability Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2586602406","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586602406?lang=en_us&edition=fundamental","pubTime":"2025-11-26 04:25","pubTimestamp":1764102327,"startTime":"0","endTime":"0","summary":"Analyst Anthony Vendetti from Maxim Group maintained a Buy rating on Dermata Therapeutics and keeping the price target at $10.00. Anthony Vendetti ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/dermata-therapeutics-strategic-shift-and-financial-stability-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/dermata-therapeutics-strategic-shift-and-financial-stability-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586090491","title":"BRIEF-Dermata Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2586090491","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586090491?lang=en_us&edition=fundamental","pubTime":"2025-11-25 02:13","pubTimestamp":1764008038,"startTime":"0","endTime":"0","summary":"BRIEF-Dermata Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million Nov 24  - Dermata Therapeutics Inc DRMA.O:DERMATA THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILINGSource text: [ID:n0001493152-25-024720]Further company coverage: DRMA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","DRMA","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586499833","title":"Dermata Therapeutics files $100M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2586499833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586499833?lang=en_us&edition=fundamental","pubTime":"2025-11-25 00:35","pubTimestamp":1764002108,"startTime":"0","endTime":"0","summary":"11:34 EST Dermata Therapeutics (DRMA) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-files-100m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-files-100m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","DRMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584501939","title":"BRIEF-Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584501939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584501939?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:08","pubTimestamp":1763464096,"startTime":"0","endTime":"0","summary":"BRIEF-Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC FilingNov 18  - Dermata Therapeutics Inc DRMA.O:DERMATA THERAPEUTICS INC - ON NOV 17, TERMINATES LICENSE AGREEMENT WITH VILLANI DATED MARCH 31, 2017 - SEC FILINGDERMATA THERAPEUTICS INC - TERMINATION LINKED TO STRATEGIC SHIFT TO OTC SKIN CARE - SEC FILINGDERMATA THERAPEUTICS : VILLANI WILL NOT BE ENTITLED TO RECEIVE ANY FURTHER MILESTONES OR OTHER PAYMENTS DUE AFTER TERMINATION DATEFurther company coverage: DRMA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DRMA","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dermatarx.com;ir.dermatarx.com","stockEarnings":[{"period":"1week","weight":-0.0526},{"period":"1month","weight":-0.0156},{"period":"3month","weight":-0.3115},{"period":"6month","weight":-0.5855},{"period":"1year","weight":-0.8444},{"period":"ytd","weight":-0.4569}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.070436},{"month":2,"riseRate":0,"avgChangeRate":-0.221628},{"month":3,"riseRate":0.4,"avgChangeRate":-0.164591},{"month":4,"riseRate":0.4,"avgChangeRate":-0.040018},{"month":5,"riseRate":0,"avgChangeRate":-0.141297},{"month":6,"riseRate":0.25,"avgChangeRate":-0.174977},{"month":7,"riseRate":0.25,"avgChangeRate":-0.133285},{"month":8,"riseRate":0.25,"avgChangeRate":-0.03319},{"month":9,"riseRate":0,"avgChangeRate":-0.128292},{"month":10,"riseRate":0.4,"avgChangeRate":-0.136086},{"month":11,"riseRate":0.2,"avgChangeRate":-0.072999},{"month":12,"riseRate":0.2,"avgChangeRate":-0.194478}],"exchange":"NASDAQ","name":"Dermata Therapeutics Inc","nameEN":"Dermata Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Dermata Therapeutics Inc(DRMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Dermata Therapeutics Inc,DRMA,Dermata Therapeutics Inc股票,Dermata Therapeutics Inc股票老虎,Dermata Therapeutics Inc股票老虎国际,Dermata Therapeutics Inc行情,Dermata Therapeutics Inc股票行情,Dermata Therapeutics Inc股价,Dermata Therapeutics Inc股市,Dermata Therapeutics Inc股票价格,Dermata Therapeutics Inc股票交易,Dermata Therapeutics Inc股票购买,Dermata Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Dermata Therapeutics Inc(DRMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction